Eli Lilly and Company (LLY) Fair Value & Analysis
Healthcare · US · Market cap $1.0T
Eli Lilly and Company
LLY · US
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Share price +11.3% over the past month.
Price vs Fair Value (12 months)
12‑month range $559.20 – $1,107 · fair‑value band $221.23 – $582.33 · the $1,107 price screens above the $395.92 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Eli Lilly and Company (LLY) currently trades at $1,107, while our model-based Fair Value estimate is $395.92 — implying the stock looks roughly 64.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Eli Lilly and Company generated revenue of $72.2B at a net margin of 35.0%. Revenue grew 55.5% year over year. It earns a return on equity of 107.5%. Net debt stands at $35.3B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immuno…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Eli Lilly and Company reported revenue of $65.2B in FY2025 versus $28.3B in FY2021, a compound +23.2%/yr. Reported net income was $20.6B in FY2025, compounding +38.7%/yr from FY2021.
Open the full interactive analysis →
Recent news
- Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?
- Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
- Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
- ŌURA and LillyDirect to Expand Support for People Using GLP-1 Therapies with New Tools and Savings Options
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Johnson & Johnson, JNJ | 4,128 MXN | 2,944 MXN | -29% |
| AbbVie Inc ABBV | $224.95 | $129.90 | -42% |
| Roche Holding ROGN | 7,050 MXN | 5,381 MXN | -24% |
| Merck & Co MRCK34 | R$72.90 | R$13.54 | -81% |
| AstraZeneca PLC A1ZN34 | R$157.11 | R$108.37 | -31% |
| Novartis AG N1VS34 | R$76.88 | R$56.26 | -27% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Eli Lilly and Company (LLY) undervalued?
What is the fair value of LLY?
What is the quality score of LLY?
What is the revenue of Eli Lilly and Company (LLY)?
What is the net profit margin of LLY?
Does Eli Lilly and Company pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.